# US 2011/0301082 A1 · Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0301082 A1
- Document ID: US20110301082A1
- Status: Published application
- Kind: A1
- Application number: 13/202,124
- Filed: 2010-02-15
- Published: 2011-12-08
- Earliest claimed: 2009-02-25
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Songnian Lin; Libo Xo; Edward Metzger; Emma R. Parmee; Sheryl D. Debenham
- Web page: https://patentgrep.com/patent/US20110301082A1

## CPC

- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type (2) diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

## Claims

### Claim 1

A compound represented by formula I:
or a pharmaceutically acceptable salt thereof wherein:
each R1 represents H or is selected from the group consisting of: halo, CN, OH, NO2, CO2Ra, NRaRb, S(O)pRa, C1-10alkyl, C2-10alkenyl or C1-10alkoxy, the alkyl and alkenyl portions of C1-10alkyl, C2-10alkenyl and C1-10alkoxy being optionally substituted with 1-5 halo atoms up to perhalo; and further optionally substituted with 1 group selected from OH, oxo and C1-6alkoxy;
p represents 0, 1 or 2;
each Ra and Rb independently represents H or C1-4alkyl optionally substituted with 1-5 halo atoms up to perhalo; and further optionally substituted with 1 group selected from OH, oxo and C1-6alkoxy;
R2 represents C1-6alkyl or C2-6alkenyl, each optionally substituted with 1-5 halo atoms up to perhalo, and further optionally substituted with 1 group selected from OH, oxo and C1-6alkoxy;
each R3 represents H or halo, or 1-2 R3 groups represent H or halo and the remainder represent a member selected from the group consisting of: CN; OH; NO2; CO2Ra; NRaRb; S(O)pRa; phenyl or 5-6 membered heteroaryl containing 1-3 nitrogen atoms and 0-1 oxygen or sulfur atom, said phenyl and heteroaryl being optionally substituted with 1-3 halo atoms and 1-2 members selected from the group consisting of: S(O)pRa, C1-3alkyl, C1 -3 alkoxy, haloC1-3alkyl and haloC1-3alkoxy; C1-10alkyl; C2-10alkenyl and C1-10alkoxy, the alkyl and alkenyl portions of C1-10alkyl, C2-10alkenyl and C1-10alkoxy being optionally substituted with 1-5 halo atoms up to perhalo; and further optionally substituted with 1 group selected from OH, oxo, NRaRb, and C1-6alkoxy;
and R4 represents H or is selected from the group consisting of: C1-4alkyl, haloC1-4alkyl and phenyl optionally substituted with 1-3 halo groups and 1-2 C1-3alkyl, haloC1-3alkyl, OC1-3alkyl and haloOC1-3 alkyl groups.

### Claim 2 (depends on 1)

A compound in accordance with claim 1, or a pharmaceutically acceptable salt thereof, wherein;
each R1 represents H or is selected from the group consisting of: halo, CN, C1-10alkyl, or C1-10alkoxy, the alkyl portions of C1-10alkyl, and C1-10alkoxy being optionally substituted with 1-5 halo atoms up to perhalo; and further optionally substituted with 1 group selected from OH, oxo and C1-6alkoxy.

### Claim 3 (depends on 2)

A compound in accordance with claim 2, or a pharmaceutically acceptable salt thereof, wherein:
each R1 represents H or is selected from the group consisting of: halo selected from chloro and fluoro, CN, C1-4alkyl, or C1-4alkoxy, the alkyl portions of C1-4alkyl, and C1-4alkoxy being optionally substituted with 1-3 halo atoms selected from chloro and fluoro; and further optionally substituted with 1 group selected from OH and OCH3.

### Claim 4 (depends on 3)

A compound in accordance with claim 3, or a pharmaceutically acceptable salt or solvate thereof, wherein:
each R1 represents H or is selected from the group consisting of: halo selected from chloro and fluoro, and CN.

### Claim 5 (depends on 1)

A compound in accordance with claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R2 represents C1-3alkyl or C2-4alkenyl, each optionally substituted with 1-3 halo atoms selected from chloro and fluoro, and further optionally substituted with 1 group selected from OH, oxo and OCH3.

### Claim 6 (depends on 5)

A compound in accordance with claim 5, or a pharmaceutically acceptable salt thereof, wherein:
R2 represents n-propyl or allyl, each optionally substituted with 1-3 halo atoms selected from chloro and fluoro.

### Claim 7 (depends on 6)

A compound in accordance with claim 6, or a pharmaceutically acceptable salt thereof, wherein:
R2 represents n-propyl or allyl.

### Claim 8 (depends on 1)

A compound in accordance with claim 1, or a pharmaceutically acceptable salt thereof, wherein:
each R3 represents H or halo, or 1-2 R3 groups represent H or halo and the remainder represent a member selected from the group consisting of: CN; S(O)pRa; phenyl or 5-6 membered heteroaryl containing 1-3 nitrogen atoms and 0-1 oxygen or sulfur atom, said phenyl and heteroaryl being optionally substituted with 1-3 halo atoms and 1-2 members selected from the group consisting of: S(O)pRa, C1-3alkyl, C1-3alkoxy, haloC1-3alkyl and haloC1-3alkoxy; C1-10alkyl and C1-10alkoxy, the alkyl portions of C1-10alkyl and C1-10alkoxy being optionally substituted with 1-3 halo atoms up to perhalo,
p is 0 or 2, and Ra is H or C1-4alkyl optionally substituted with 1-3 halo atoms.

### Claim 9 (depends on 8)

A compound in accordance with claim 8, or a pharmaceutically acceptable salt thereof, wherein:
each R3 represents H or halo selected from chloro, fluoro and bromo, or 1-2 R3 groups represent H or halo selected from chloro, fluoro and bromo, and the remainder represent a member selected from the group consisting of: CN; C1-4alkyl and C1-4alkoxy, the alkyl and portions of C1-4alkyl and C1-4alkoxy being optionally substituted with 1-3 halo atoms selected from chloro and fluoro; SO2C1-4alkyl; phenyl or 5-6 membered heteroaryl containing 1-2 nitrogen atoms, said phenyl and heteroaryl being optionally substituted with 1-3 halo atoms selected from chloro, fluoro and bromo, and 1 member selected from the group consisting of: SO2C1-3alkyl, C1-3alkyl, C1-3alkoxy, haloC1-3alkyl and haloC1-3alkoxy.

### Claim 10 (depends on 9)

A compound in accordance with claim 9, or a pharmaceutically acceptable salt thereof, wherein:
each R3 represents H or halo selected from chloro and fluoro, or 1-2 R3 groups represent H or halo selected from chloro and fluoro, and the remainder represent a member selected from the group consisting of: bromo, CH3, CF3, CN; phenyl or pyridyl, said phenyl and pyridyl being optionally substituted with 1-2 halo atoms selected from chloro and fluoro, and 1 member selected from the group consisting of: CH3, OCH3, CF3, OCF3, and SO2CH3.

### Claim 11 (depends on 1)

A compound in accordance with claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R4 represents H or is selected from the group consisting of: C1-3alkyl, haloC1-3alkyl and phenyl optionally substituted with 1-3 halo groups selected from chloro and fluoro, and 1-2 C1-2alkyl, CF3, OCH3 and OCF3 groups.

### Claim 12 (depends on 1)

A compound in accordance with claim 1, represented by formula I:
or a pharmaceutically acceptable salt thereof, wherein:
each R1 represents H or is selected from the group consisting of: halo, CN, C1-10alkyl, or C1-10alkoxy, the alkyl portions of C1-10alkyl, and C1-10alkoxy being optionally substituted with 1-5 halo atoms up to perhalo; and further optionally substituted with 1 group selected from OH, oxo and C1-6alkoxy;
R2 represents C1-3alkyl or C2-4alkenyl, each optionally substituted with 1-3 halo atoms selected from chloro and fluoro, and further optionally substituted with 1 group selected from OH, oxo and OCH3;
each R3 represents H or halo, or 1-2 R3 groups represent H or halo and the remainder represent a member selected from the group consisting of: CN; S(O)pRa; phenyl or 5-6 membered heteroaryl containing 1-3 nitrogen atoms and 0-1 oxygen or sulfur atom, said phenyl and heteroaryl being optionally substituted with 1-3 halo atoms and 1-2 members selected from the group consisting of: S(O)pRa, C1-3alkyl, C1-3alkoxy, haloC1-3alkyl and haloC1-3alkoxy; C1-10alkyl and C1-10alkoxy, the alkyl portions of C1-10alkyl and C1-10alkoxy being optionally substituted with 1-3 halo atoms up to perhalo,
is 0 or 2, and Ra is H or C1-4alkyl optionally substituted with 1-3 halo atoms, and
R4 represents H or is selected from the group consisting of: C1-3alkyl, haloC1-3alkyl and phenyl optionally substituted with 1-3 halo groups selected from chloro and fluoro, and 1-2 C1-2alkyl, CF3, OCH3 and OCF3 groups.

### Claim 13 (depends on 1)

A compound in accordance with claim 1, selected from the following:
TABLE 1
EXAMPLE
R3
R4
5
5-CF3
H
6
5-CF3, 7-Cl
H
7
5-F, 7-F
H
8
5-Cl, 7-Cl
H
9
5-CF3
Me
10
5-F, 7-F
Me
11
5-Cl, 7-Me
Me
12
5-Cl, 7-Cl
Me
TABLE 2
EXAMPLE
R3
R4
13
5-CF3
Me
14
5-CF3, 7-Cl
Et
15
5-CF3, 7-Cl
n-Pr
16
5-CF3, 7-Cl
i-Pr
17
5-CF3, 7-Cl
—CH2CF3
18
5-F, 7-F
Me
19
5-Cl, 7-Cl
Me
20
5-Cl, 7-Me
Me
TABLE 3
EXAMPLE
Q
22
Br
23
H
24
25
26
27
28
29
30
31
32
33
34
35
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a compound in accordance with claim 1 or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

### Claim 15 (depends on 14)

A pharmaceutical composition in accordance with claim 14 further comprised of a member selected from the group consisting of: simvastatin, mevastatin, ezetimibe, atorvastatin, metformin, sibutramine, orlistat, Qnexa, topiramate, naltrexone, bupriopion, phentermine, losartan, hydrochlorothiazide, buformin, phenformin, troglitazone, pioglitazone, rosiglitazone, insulin, somatostatin, voglibose, miglitol, acarbose, sitagliptin, vildagliptin, saxagliptin, alogliptin, acetohexamide, carbutamide, chlorpropamide, glibornuride, gliclazide, glimerpiride, glipizide, gliquidine, glisoxepid, glyburide, glyhexamide, glypinamide, phenbutamide, tolazamide, tolbutamide, tolcyclamide, nateglinide, repaglinide, rimonabant and taranabant.

### Claim 16 (depends on 1)

A method of treating type 2 diabetes mellitus in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with claim 1 or a pharmaceutically acceptable salt thereof in an amount that is effective to treat said type 2 diabetes mellitus.

### Claim 17 (depends on 1)

A method of delaying the onset of type 2 diabetes mellitus in a mammalian patient in need thereof, comprising administering to the patient a compound in accordance with claim 1 or a pharmaceutically acceptable salt thereof in an amount that is effective to delay the onset of said type 2 diabetes mellitus.

### Claim 18 (depends on 1)

A method of treating hyperglycemia, diabetes or insulin resistance in a mammalian patient in need of such treatment which comprises administering to said patient an effective amount of a compound in accordance with claim 1 or a pharmaceutically acceptable salt thereof

### Claim 19 (depends on 1)

A method of treating non-insulin dependent diabetes mellitus in a mammalian patient in need of such treatment comprising administering to the patient an anti-diabetic effective amount of a compound in accordance with claim 1 or a pharmaceutically acceptable salt thereof

### Claim at position 20

-24. (canceled)

### Claim 25 (depends on 16)

A method in accordance with claim 16 further comprising administering to the patient a compound selected from the group consisting of: simvastatin, mevastatin, ezetimibe, atorvastatin, sibutramine, orlistat, Qnexa, topiramate, naltrexone, bupriopion, phentermine, losartan, hydrochlorothiazide, buformin, metformin, phenformin, troglitazone, pioglitazone, rosiglitazone, insulin, somatostatin, voglibose, miglitol, acarbose, sitagliptin, vildagliptin, saxagliptin, alogliptin, acetohexamide, carbutamide, chlorpropamide, glibornuride, gliclazide, glimerpiride, glipizide, gliquidine, glisoxepid, glyburide, glyhexamide, glypinamide, phenbutamide, tolazamide, tolbutamide, tolcyclamide, nateglinide, repaglinide, rimonabant and taranabant.
